Henderson Mary Elizabeth 4

What Happened
Mary Elizabeth Henderson, Senior Vice President, Technical Operations at Jazz Pharmaceuticals (JAZZ), reported two transactions on 2026-02-26. She sold 5,343 ordinary shares in open-market transactions for a weighted average price of $194.49, generating $1,039,134 in proceeds. On the same date she was granted 4,447 restricted stock units (RSUs) (no immediate cash value reported).

Key Details

• Transaction dates: February 26, 2026; Form 4 filed March 2, 2026 (appears timely).
• Sale: 5,343 shares disposed, weighted average price $194.49, proceeds $1,039,134; reported sale prices ranged $194.19–$194.50.
• Grant: 4,447 RSUs granted (acquisition reported at $0 because RSUs convert to shares only upon vesting).
• Shares owned after transaction: not reported in the provided filing excerpt.
• Footnotes: F1 — RSUs issued under the 2011 Equity Incentive Plan and vest in equal annual installments over four years with a vesting commencement date of March 5, 2026. F2 — shares sold to satisfy tax obligations from vesting of previously granted RSUs. F3 — sale executed in multiple trades; weighted-average price reported with range provided.

Context
The sale was reported as a routine open-market disposal and — per the filing footnote — some sales were to satisfy tax withholding from prior RSU vesting, which is a common, non-directional reason insiders sell shares. The RSU grant represents future contingent share awards that will vest over four years rather than immediate share ownership.